b"MyAML Clinical InformationUnderstanding the clonal architecture of AML patients is vital for successful treatments. 1Many different mutations,MyAML identifies all somatic mutations, large and small epigenetic aberrations, or downstream abnormalities caninsertions/deletion, and translocations under NCCN/ELN generate the same clinical treatment plan. However, theseguidelines, as well as novel somatic variants that may have differences are responsible for the variable responsesprognostic significance for AML.observed with therapy, which is a major feature in patientsScreening with MyAML allows informed treatment decisions with AML. 2Therefore, since varied somatic mutations affectto be made once all the relevant mutations are known, patient outcomes, conventional genotyping is no longer theboth in the prevalent clones, as well as the 'secondary' or most suitable method for screening patients.'tertiary' clones, which could become the new prominent MyAML is a CLIA-validated assay that identifies clinicallyclones leading to refractory and relapsed disease.actionable, pathogenic, and potentially pathogenic mutations in 194 genes associated with AML. Using the latest version in Next-Generation Sequencing chemistry,List of Genes on the MyAML Panel Other GenesABCC1 ACVR2B ADRBK1 AKAP13 ANKRD24 ARID2 ARID4B ASXL1 ASXL2 ASXL3 Structural Rearrangements BCOR BCORL1 BRINP3 BRPF1 BUB1 CACNA1E CBL CBX5 CBX7 CDC73 CEP164 CPNE3 CSF1R CSTF2T CTCF CYLD DCLK1 DDX1 DDX23 DHX32 DIS3 DNAH9 Inv(16) t(16;16) t(8;21) t(15;17) t(9;11) inv(3) t(3;3) t(6;9) t(9;22)DNMT1 DNMT3B DYRK4 EED EGFR EP300 EPHA2 EPHA3 ETV3 EZH2 FANCC GATA1 GATA2 GFI1 GLI1 HDAC2 HDAC3 HNRNPK HRAS IKZF1 JAK1 JAK2 JAK3 GenesJMJD1C KDM2B KDM3B KDM6A KDM6B KMT2B KMT2C KRAS MAPK1 METTL3 CEBPA DNMT3A FLT3 IDH1 IDH2 KIT NPM1MST1R MTA2 MTOR MXRA5 MYB MYC MYLK2 MYO3A NF1 NOTCH1 NOTCH2 NRAS NRK OBSCN PAPD5 PAX5 PDGFRA PDGFRB PDS5B PDSS2 PHF6 PKD1L2 PLRG1 POLR2A PRDM16 PRDM9 PRKCG PRPF3 PRPF40B PRPF8 PTEN PTPN11 Other Fusions and Gene Rearrangements PTPN14 PTPRT RAD21 RBBP4 RBMX RPS6KA6 SAP130 SCML2 SETBP1 SETD2 SF1 ABL1 ADGRG7 AFF1 BCR CBFB CREBBP DEK EIF4E2 ELL ETV6 GAS6 GAS7SF3A1 SF3B1 SMC1A SMC3 SMC5 SMG1 SNRNP200 SOS1 SPEN SRRM2 SRSF2 KAT6A KAT6B KMT2A MECOM MKL1 MLLT10 MLLT1 MLLT3 MLLT4 MYH11SRSF6 STAG2 STK32A STK33 STK36 SUDS3 SUMO2 SUPT5H SUZ12 TCF4 TET1 NSD1 NUP214 NUP98 PICALM PML RARA RBM15 RPN1 RUNX1 RUNX1T1 SEPT5TET2 THRB TP53 TRA2B TRIO TTBK1 TYK2 TYW1 U2AF1 U2AF1L4 U2AF2 UBA3 SET TFG TMEM255BWAC WAPAL WEE1 WNK3 WNK4 WT1 ZBTB33 ZBTB7B ZRSR2References1.Dhner K et al. (2014) Intermediate-risk acute myeloid leukemia therapy: current and future. Hematology Am Soc HematolEduc Program 1,34-43.2.Estey EH (2014) Acute myeloid leukemia: 2014 update on risk-stratification and management. Am J Hematol 89:1063-1081.50"